8-K filing — Shattuck Labs, Inc. (STTK)
Filed: 2026-11-05 AccNo: 0001628280-26-070613 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including progress with SL-325 and SL-846.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Evercore Initiates Coverage on Shattuck Labs with Buy Rating
Evercore analyst Jonathan Miller has initiated coverage of Shattuck Labs with a 'Buy' rating and a price target of $10.
UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17
UBS analyst Alice Nettleton initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Buy rating and announces Price Target of $17.
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14
Wedbush analyst David Nierengarten maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and raises the price target from $11 to $14.
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19
Needham analyst Joseph Stringer maintains Shattuck Labs (NASDAQ:STTK) with a Buy and raises the price target from $17 to $19.